IDBS Blog | 13th April 2018
The Growth of Biologics Means More Data
The Biologics sector is continuing to grow at an accelerated pace – and it’s showing no signs of slowing down.
Just recently, Pharmaceutical Product Development, LLC (PPD) announced the expansion of its GMP analytical laboratory, nearly doubling its analytics testing capacity. According to Jon Denissen, the company’s Senior Vice President, this expansion “enables us to meet the ever-growing needs of our clients for GMP testing of large molecule products.”
The growth in interest in large molecule therapeutics means more research will be undertaken and that means much more data will be produced. Good data – timely, precise and easily accessible – is crucial in drug development and production.
Amazingly, many pharmaceutical companies and research institutions still rely heavily on paperwork for managing data – a strenuous and inefficient method. The need to transform this process with technology is clear; electronic lab notebook software enables faster and more secure capture, compute and integration of critical data. It will also support more effective collaboration between organizations involved in joint research.
Keeping up with the pace of innovation in biologics means keeping up with the data explosion that accompanies it. This means ensuring you put in place the critical tools you need to be effective.